financetom
Business
financetom
/
Business
/
Anavex Life Sciences Falls in Premarket Trading After Alzheimer's Drug Receives EU Regulatory Setback
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Anavex Life Sciences Falls in Premarket Trading After Alzheimer's Drug Receives EU Regulatory Setback
Nov 14, 2025 5:42 AM

08:18 AM EST, 11/14/2025 (MT Newswires) -- Anavex Life Sciences ( AVXL ) shares were down more than 43% on Friday after a European regulator informed the company of a negative trend vote on its marketing authorization application for blarcamesine treating early Alzheimer's disease.

Anavex said it plans to request a re-examination of the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency on the application after it adopts a formal opinion on the application in December.

The company said it plans to provide relevant biomarker data, based on feedback from the agencies and the Alzheimer's disease community.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved